CD34 and type 2 diabetes mellitus: Thus, the 16-week treatment with Canagliflozin in combination with metformin and/or insulin of T2DM patients increased EPCs (CD34+) expression of SDF1 and the migratory ability of EPCs in response to SDF1-α [196].